103 related articles for article (PubMed ID: 24816038)
1. In search for genetic determinants of clinically meaningful differential cardiovascular event reduction by pravastatin in the PHArmacogenetic study of Statins in the Elderly at risk (PHASE)/PROSPER study.
Postmus I; Johnson PC; Trompet S; de Craen AJ; Slagboom PE; Devlin JJ; Shiffman D; Sacks FM; Kearney PM; Stott DJ; Buckley BM; Sattar N; Ford I; Westendorp RG; Jukema JW
Atherosclerosis; 2014 Jul; 235(1):58-64. PubMed ID: 24816038
[TBL] [Abstract][Full Text] [Related]
2. Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses.
Trompet S; de Craen AJ; Postmus I; Ford I; Sattar N; Caslake M; Stott DJ; Buckley BM; Sacks F; Devlin JJ; Slagboom PE; Westendorp RG; Jukema JW;
BMC Med Genet; 2011 Oct; 12():131. PubMed ID: 21977987
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy.
Shiffman D; Trompet S; Louie JZ; Rowland CM; Catanese JJ; Iakoubova OA; Kirchgessner TG; Westendorp RG; de Craen AJ; Slagboom PE; Buckley BM; Stott DJ; Sattar N; Devlin JJ; Packard CJ; Ford I; Sacks FM; Jukema JW
PLoS One; 2012; 7(5):e38240. PubMed ID: 22666496
[TBL] [Abstract][Full Text] [Related]
4. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
Packard CJ; Ford I; Robertson M; Shepherd J; Blauw GJ; Murphy MB; Bollen EL; Buckley BM; Cobbe SM; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG;
Circulation; 2005 Nov; 112(20):3058-65. PubMed ID: 16275871
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of statins: achievements, whole-genome analyses and future perspectives.
Postmus I; Verschuren JJ; de Craen AJ; Slagboom PE; Westendorp RG; Jukema JW; Trompet S
Pharmacogenomics; 2012 May; 13(7):831-40. PubMed ID: 22594514
[TBL] [Abstract][Full Text] [Related]
6. KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly.
Akao H; Polisecki E; Kajinami K; Trompet S; Robertson M; Ford I; Jukema JW; de Craen AJ; Westendorp RG; Shepherd J; Packard C; Buckley BM; Schaefer EJ
Atherosclerosis; 2012 Feb; 220(2):456-62. PubMed ID: 22192511
[TBL] [Abstract][Full Text] [Related]
7. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Zhou Z; Rahme E; Pilote L
Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
[TBL] [Abstract][Full Text] [Related]
8. Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: a post hoc analysis of the MEGA Study.
Nishiwaki M; Ikewaki K; Ayaori M; Mizuno K; Ohashi Y; Ohsuzu F; Ishikawa T; Nakamura H;
J Cardiol; 2013 Mar; 61(3):196-200. PubMed ID: 23265677
[TBL] [Abstract][Full Text] [Related]
9. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.
Polisecki E; Muallem H; Maeda N; Peter I; Robertson M; McMahon AD; Ford I; Packard C; Shepherd J; Jukema JW; Westendorp RG; de Craen AJ; Buckley BM; Ordovas JM; Schaefer EJ;
Atherosclerosis; 2008 Sep; 200(1):109-14. PubMed ID: 18261733
[TBL] [Abstract][Full Text] [Related]
10. Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly.
Akao H; Polisecki E; Kajinami K; Trompet S; Robertson M; Ford I; Jukema JW; de Craen AJ; Westendorp RG; Shepherd J; Packard C; Buckley BM; Schaefer EJ
Atherosclerosis; 2012 Feb; 220(2):413-7. PubMed ID: 22189199
[TBL] [Abstract][Full Text] [Related]
11. Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies.
Trompet S; Postmus I; Slagboom PE; Heijmans BT; Smit RA; Maier AB; Buckley BM; Sattar N; Stott DJ; Ford I; Westendorp RG; de Craen AJ; Jukema JW
Eur J Clin Pharmacol; 2016 Apr; 72(4):431-7. PubMed ID: 26686871
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
Sattar N; Murray HM; McConnachie A; Blauw GJ; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Murphy MB; Packard CJ; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG; Shepherd J;
Circulation; 2007 Feb; 115(8):981-9. PubMed ID: 17283264
[TBL] [Abstract][Full Text] [Related]
13. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
[TBL] [Abstract][Full Text] [Related]
14. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.
Chasman DI; Giulianini F; MacFadyen J; Barratt BJ; Nyberg F; Ridker PM
Circ Cardiovasc Genet; 2012 Apr; 5(2):257-64. PubMed ID: 22331829
[TBL] [Abstract][Full Text] [Related]
15. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP;
J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964
[TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
17. Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin.
Nakamura H;
Atheroscler Suppl; 2007 Aug; 8(2):13-7. PubMed ID: 17586102
[TBL] [Abstract][Full Text] [Related]
18. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.
Boekholdt SM; Sacks FM; Jukema JW; Shepherd J; Freeman DJ; McMahon AD; Cambien F; Nicaud V; de Grooth GJ; Talmud PJ; Humphries SE; Miller GJ; Eiriksdottir G; Gudnason V; Kauma H; Kakko S; Savolainen MJ; Arca M; Montali A; Liu S; Lanz HJ; Zwinderman AH; Kuivenhoven JA; Kastelein JJ
Circulation; 2005 Jan; 111(3):278-87. PubMed ID: 15655129
[TBL] [Abstract][Full Text] [Related]
19. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Cannon CP; Braunwald E; McCabe CH; Rader DJ; Rouleau JL; Belder R; Joyal SV; Hill KA; Pfeffer MA; Skene AM;
N Engl J Med; 2004 Apr; 350(15):1495-504. PubMed ID: 15007110
[TBL] [Abstract][Full Text] [Related]
20. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
